StockData
Aktis Oncology, Inc. logo

Aktis Oncology, Inc. (AKTS) stock

AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.10−0.21 (-1.29%)

Close on Nov 18, 2026Market cap $895.47MP/E –Yield –

Aktis Oncology revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$3.91M+143.9%
Q2 FY2026Jun 30, 2026$3.38M+133.9%
Q1 FY2026Mar 31, 2026$3.23M–
Q3 FY2025Sep 30, 2025$1.58M–
Q2 FY2025Jun 30, 2025$1.60M–
Q1 FY2025Mar 31, 2025$1.45M–

More Aktis Oncology figures

See a number that looks wrong?